Dalbavancin and telavancin: Novel lipoglycopeptides for the treatment of Gram-positive infections

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 1, 2008, Pages 67-81

  Zhanel, George G ^a   Trapp, Shannon ^a   Gin, Alfred S ^a   DeCorby, Mel ^a   Lagacé Wiens, Philippe R S ^a   Rubinstein, Ethan ^a   Hoban, Daryl J ^a   Karlowsky, James A ^a  

^a HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Dalbavancin; Telavancin; Vancomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFAZOLIN; CEPHALOSPORIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; CARDIOTOXICITY; CATHETER INFECTION; CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GRAM POSITIVE BACTERIUM; HEART REPOLARIZATION; HUMAN; INSOMNIA; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE DRUG DOSE; NAUSEA; NONHUMAN; OTOTOXICITY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; QT INTERVAL; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; STRUCTURE ACTIVITY RELATION; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VESTIBULAR DISORDER;

AMINOGLYCOSIDES; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LIPOSOMES; TEICOPLANIN;

EID: 40649118770     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.1.67     Document Type: Review

References (64)

1. Schweiger ES, Weinberg JM. Novel antibacterial agents for skin and skin structure infections. J. Am. Acad. Dermatol. 50(3), 331-340 (2004).
2. Pope SD, Roecker AM. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotheraphy 26(7), 908-918 (2006).
3. Lin G, Smith K, Ednie LM, Appelbaum PC. Antipneumococcal activity of dalbavancin compared to other agents. Antimicrob. Agents Chemother. 49(12), 5182-5184 (2005).
4. Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microbiol. Infect. Dis. 54(2), 149-153 (2006).
5. Giamarellou H. Treatment options for multidrug-resistant bacteria. Expert. Rev. Anti Infect. Ther. 4(4), 601-618 (2006).
6. Ellis MW, Lewis JS 2nd. Treatment approaches for community-acquired methicillin-resistant Staphyloccus aureus infections. Curr. Opin. Infect. Dis. 18(6), 496-501 (2005).
7. Dorr MB, Jabes D, Cavaleri M et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J. Antimicrob. Chemother. 55(Suppl. 2), ii25-ii30 (2005).
8. Darouiche RO, Mansouri MD. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vitro. J. Infect. 50(3), 206-209 (2005).
9. Barrett JF. Recent developments in glycopeptide antibacterials. Curr. Opin. Investig. Drugs 6(8), 781-790 (2005).
10. Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin. Investig. Drugs 12(3), 379-399 (2003).
11. Leadbetter MR, Adams SM, Bazzini B et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot. (Tokyo) 57(5), 326-336 (2004).
12. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin. Pharmacokinet. 11(4), 257-282 (1986).
13. Kanafani ZA. Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Expert. Rev. Anti Infect. Ther. 4(5), 743-749 (2006).
14. Stryjewski ME, O'Riordan WD, Lau WK et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin. Infect. Dis. 40(11), 1601-1607 (2005).
15. Chen AY, Zervos MJ, Vazquez JA. Dalbavancin: a novel antimicrobial. Int. J. Clin. Pract. 61(5), 853-863 (2007).
16. Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41(10), 1407-1415 (2005).
17. Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49(8), 3163-3165 (2005).
18. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49(1), 195-201 (2005).
19. Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother. 50(2), 788-790 (2006).
20. Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. 4(5), 471-478 (2004).
21. Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin. Investig. Drugs 16(5), 717-733 (2007).
22. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob. Chemother. 55(Suppl. 2), ii15-ii20 (2005).
23. Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: a novel lipoglycopeptide for serious gram positive infections. Expert Opin. Investig. Drugs 16(3), 347-357 (2007).
24. Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr. Opin. Investig. Drugs 7(8), 740-749 (2006).
25. Padmanabhan RA, Larosa SP, Tomecki KJ. What's new in antibiotics? Dermatol. Clin. 23(2), 301-312 (2005).
26. Lin SW, Carver PL, DePestel DD. Dalbavancin: a new option for the treatment of Gram-positive infections. Ann. Pharmacother. 40(3), 449-460 (2006).
27. Johnson DM, Fritsche TR, Sader HS, Jones RN. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int. J. Antimicrob. Agents 27(6), 557-560 (2006).
28. Bosso JA. The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy 25(10 Pt 2), 55S-62S (2005).
29. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58(6), 1177-1184 (2006).
30. Higgins DL, Chang R, Debabov DV et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(3), 1127-1134 (2005).
31. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 64(9), 913-936 (2004).
32. Pace JL, Yang G. Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol. 71(7), 968-980 (2006).
33. Biedenbach DJ, Ross JE, Fritsche TR, Sader HS, Jones RN. Activity of dalbavancin tested against Staphylococcus spp. and β-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J. Clin. Microbiol. 45(3), 998-1004 (2007).
34. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 48(2), 137-143 (2004).
35. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg. Infect. Larchmt) 6(3), 283-295 (2005).
36. Krause K, Benton B, Higgins D et al. Telavancin (TLV) possesses low potential for resistant mutant selection in serial poassage studies of Staphylococcus aureus and enterococci. Presented at: 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark 2-5 April (2005).
37. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J. Antimicrob. Chemother. 53(5), 797-803 (2004).
38. Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J. Antimicrob. Chemother. 60(3), 681-684 (2007).
39. Torres-Viera C, Dembry LM. Approaches to vancomycin-resistant enterococci. Curr. Opin. Infect. Dis. 17(6), 541-547 (2004).
40. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob. Agents Chemother. 51(5), 1633-1642 (2007).
41. Poulakou G, Giamarellou H. Investigational treatments for postoperative surgical site infections. Expert Opin. Investig. Drugs 16(2), 137-155 (2007).
42. Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 60(2), 406-409 (2007).
43. Hegde SS, Reyes N, Wiens T et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob. Agents Chemother. 48(8), 3043-3050 (2004).
44. Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin. Microbiol. Infect. 11(2), 95-100 (2005).
45. Appelbaum PC, Jacobs MR. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr. Opin. Microbiol. 8(5), 510-517 (2005).
46. Leighton A, Gottlieb AB, Dorr MB et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother. 48(3), 940-945 (2004).
47. Hoffman-Roberts HL, C Babcock E, Mitropoulos IF. Investigational new drugs for the treatment of resistant pneumococcal infections. Expert Opin. Investig. Drugs 14(8), 973-995 (2005).
48. Cavaleri M, Riva S, Valagussa A et al. Pharmacokinetics and excretion of dalbavancin in the rat. J. Antimicrob. Chemother. 55(Suppl. 2), ii31-ii35 (2005).
49. Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J. Antimicrob. Chemother. 58(3), 627-631 (2006).
50. Telavancin: TD 6424, TD-6424. Drugs R. D. 7(6), 384-388 (2006).
51. Reyes N, Skinner R, Kaniga K et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(10), 4344-4346 (2005).
52. Zhanel GG. Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection. Curr. Infect. Dis. Rep. 3(1), 29-34 (2001).
53. Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J. Antimicrob. Chemother. 56(2), 337-343 (2005).
54. Sahm D, Benton B, Jones M et al. Interaction of telavancin and other antimicrobial agents tested against key Gram-positive species. Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA, 27-30 Spetember (2006).
55. Seltzer E, Dorr MB, Goldstein BP et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37(10), 1298-1303 (2003).
56. Raad I, Darouiche R, Vazquez J et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin. Infect. Dis. 40(3), 374-380 (2005).
57. Stryjewski ME, Chu VH, O'Riordan WD et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50(3), 862-867 (2006).
58. Corey R, Stryjewski M, W OR et al. Telavancin for the treatment of complicated skin and skin structure infections (cSSSI): results of the ATLAS I study. Presented at: 44th Infectious Disease Society of America Toronto, Canada, October (2006)
59. Campbell KC, Kelly E, Targovnik N et al. Audiologic monitoring for potential ototoxicity in a Phase I clinical trial of a new glycopeptide antibiotic. J. Am. Acad. Audiol. 14(3), 157-168 (2003).
60. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J. Clin. Pharmacol. 44(7), 689-695 (2004).
61. Pace JL, Judice JK. Telavancin (Theravance). Curr. Opin. Investig. Drugs 6(2), 216-225 (2005).
62. DeCorby M, Laing N, Weshoweski B et al. Activity of dalbavancin against S. aureus, MRSA, S. epidermidis and VRE isolated from Canadian intensive care units: results of the CAN-ICU study. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA 17-20 Spetember (2007).
63. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 64(15), 1621-1642 (2004).
64. Guay DR. Dalbavancin: an investigational glycopeptide. Expert. Rev. Anti Infect. Ther. 2(6), 845-852 (2004).